FVH
MCID: HPT085
MIFTS: 32

Hepatitis, Fulminant Viral (FVH)

Categories: Genetic diseases, Infectious diseases, Liver diseases, Rare diseases

Aliases & Classifications for Hepatitis, Fulminant Viral

MalaCards integrated aliases for Hepatitis, Fulminant Viral:

Name: Hepatitis, Fulminant Viral 56 73
Hepatitis, Fulminant Viral, Susceptibility to 56 6
Fvh 56 73
Fulminant Viral Hepatitis 58
Liver Failure, Acute 43

Characteristics:

OMIM:

56
Inheritance:
autosomal recessive

Miscellaneous:
one patient has been reported (last curated august 2019)
acute response to hepatitis a infection


Classifications:

Orphanet: 58  
Rare hepatic diseases


External Ids:

OMIM 56 618549
MeSH 43 D017114
ICD10 via Orphanet 33 K72
Orphanet 58 ORPHA35063
MedGen 41 CN262217

Summaries for Hepatitis, Fulminant Viral

UniProtKB/Swiss-Prot : 73 Hepatitis, fulminant viral: An autosomal recessive form of fulminant viral hepatitis, a disease that strikes otherwise healthy individuals during primary infection with common liver-tropic viruses. FVH is characterized by severe liver destruction in the absence of a preexisting liver disorder, leading to encephalopathy within 8 weeks of the onset of the first symptoms.

MalaCards based summary : Hepatitis, Fulminant Viral, also known as hepatitis, fulminant viral, susceptibility to, is related to liver failure, infantile, transient and hepatitis a. An important gene associated with Hepatitis, Fulminant Viral is IL18BP (Interleukin 18 Binding Protein). The drugs Methylprednisolone and Methylprednisolone hemisuccinate have been mentioned in the context of this disorder. Affiliated tissues include liver, testes and kidney.

More information from OMIM: 618549

Related Diseases for Hepatitis, Fulminant Viral

Graphical network of the top 20 diseases related to Hepatitis, Fulminant Viral:



Diseases related to Hepatitis, Fulminant Viral

Symptoms & Phenotypes for Hepatitis, Fulminant Viral

Symptoms via clinical synopsis from OMIM:

56
Abdomen Liver:
hepatomegaly
liver failure
hepatitis, fulminant, acute

Laboratory Abnormalities:
abnormal liver enzymes

Skin Nails Hair Skin:
icterus
jaundice, acute

Immunology:
il-18bp deficiency
enhanced il18-mediated cytotoxicity

Clinical features from OMIM:

618549

Drugs & Therapeutics for Hepatitis, Fulminant Viral

Drugs for Hepatitis, Fulminant Viral (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 109)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
2
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
3 Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
4
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
5
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
6
Acetylcysteine Approved, Investigational Phase 4 616-91-1 12035
7
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7
8
Tenofovir Experimental, Investigational Phase 4 147127-20-6 464205
9 Hormone Antagonists Phase 4
10 Hormones Phase 4
11 Antiemetics Phase 4
12 Gastrointestinal Agents Phase 4
13 Anti-Inflammatory Agents Phase 4
14 Methylprednisolone Acetate Phase 4
15 glucocorticoids Phase 4
16 Neuroprotective Agents Phase 4
17 Antineoplastic Agents, Hormonal Phase 4
18 Autonomic Agents Phase 4
19 Reverse Transcriptase Inhibitors Phase 4
20 Anti-Retroviral Agents Phase 4
21 Anti-HIV Agents Phase 4
22 Respiratory System Agents Phase 4
23 Protective Agents Phase 4
24 N-monoacetylcystine Phase 4
25 Free Radical Scavengers Phase 4
26 Antidotes Phase 4
27 Expectorants Phase 4
28 Anti-Infective Agents Phase 4
29 Antiviral Agents Phase 4
30 Antioxidants Phase 4
31 Pharmaceutical Solutions Phase 4
32
Sargramostim Approved, Investigational Phase 3 83869-56-1, 123774-72-1
33
Lenograstim Approved, Investigational Phase 3 135968-09-1
34
Acetaminophen Approved Phase 2, Phase 3 103-90-2 1983
35
Formaldehyde Approved, Vet_approved Phase 2, Phase 3 50-00-0 712
36 Adjuvants, Immunologic Phase 3
37 Immunologic Factors Phase 3
38 Epoetin alfa Phase 3 113427-24-0
39 Liver Extracts Phase 2, Phase 3
40 Antipyretics Phase 2, Phase 3
41 Analgesics, Non-Narcotic Phase 2, Phase 3
42 Analgesics Phase 2, Phase 3
43 Complement C3a Phase 3
44
Phenylacetic acid Approved Phase 2 103-82-2 999
45
Allopurinol Approved Phase 1, Phase 2 315-30-0 2094
46
Aspartic acid Approved, Nutraceutical Phase 2 56-84-8 5960
47
Ornithine Approved, Nutraceutical Phase 2 3184-13-2, 70-26-8 6262
48 Mitogens Phase 1, Phase 2
49
Bilirubin Phase 2 69853-43-6, 635-65-4 21252250 5280352
50 Antibiotics, Antitubercular Phase 2

Interventional clinical trials:

(show top 50) (show all 78)
# Name Status NCT ID Phase Drugs
1 Assessment of Coagulation Abnormalities in Acute on Chronic Liver Failure Patients Using Thromboelastography Unknown status NCT02757170 Phase 4
2 Safety and Efficacy of Steroids in the Management of Fulminant Hepatic Failure Due to Hepatitis A Virus in the Pediatric Age Group Completed NCT02375867 Phase 4 prednisolone;methylprednisolone
3 Tenofovir Reduces Morbidity and Mortality in Patients With Spontaneous Reactivation of Hepatitis B Presenting as Acute-on-chronic Liver Failure (ACLF): A Randomized Placebo Controlled Trial Completed NCT01074645 Phase 4 Tenofovir disoproxil fumarate (TDF)
4 Influence of Methylprednisolone Pulse Therapy on Liver Function in Patients With Graves' Orbitopathy Completed NCT03667157 Phase 4 every week IVMP therapy;very high doses IVMP therapy
5 A Multi-Center Trial to Study Acute Liver Failure: N-Acetylcysteine (NAC) Open Label Use Study Terminated NCT00896025 Phase 4 N-acetylcysteine
6 Randomized Study of Acetylcysteine in Patients With Acute Liver Failure Not Caused by Acetaminophen Completed NCT00004467 Phase 3 N-acetylcysteine (NAC);Placebo
7 A Multi-center Study of the Safety and Efficacy of N-acetylcysteine in the Treatment of Acute Liver Failure in Pediatric Patients Not Caused by Acetaminophen. Completed NCT00248625 Phase 3 N-acetylcysteine;Placebo
8 Randomized Placebo-controlled Trial to Assess the Efficacy of Granulocyte Colony-stimulating Factor (G-CSF) and Erythropoetin (EPO) in the Survival of Patients With Acute-on-chronic Liver Failure (ACLF) Completed NCT01383460 Phase 3 Granulocyte Colony-stimulating Factor (G-CSF) and Erythropoetin (EPO);Placebo
9 13C-Methacetin Breath Test for the Prediction of Outcome in in Acute Liver Injury or Acute Liver Failure Active, not recruiting NCT02786836 Phase 2, Phase 3 13C-Methacetin
10 A Randomized, Open-Label, Multicenter, Controlled Study to Assess Safety and Efficacy of ELAD® in Subjects With Severe Acute Alcoholic Hepatitis (sAAH) and Lille Score Failure Terminated NCT01829347 Phase 3
11 Registry Protocol for Tracking the Incidence of Transplant, the Incidence and Type of Cancer, and Survival Rate of Subjects Participating in Protocol VTI-206 (NCT00973817) Withdrawn NCT01452295 Phase 2, Phase 3 ELAD (Extracorporeal Liver Assist System)
12 Phase I/II Study of Recombinant Human Hepatocyte Growth Factor in Fulminant and Late-Onset Hepatic Failure Unknown status NCT00225901 Phase 1, Phase 2 Recombinant human hepatocyte growth factor
13 A Multicentre, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy and the Safety of ALF-5755 in Patients With Nonacetaminophen Severe Acute Hepatitis and Early Stage Acute Liver Failure Unknown status NCT01318525 Phase 2 ALF-5755;Saline solution (0.9% NaCl)
14 Molecular Adsorbent Recirculating System (MARS®) for the Treatment of Patients With Hypoxic Hepatitis - a Prospective Randomized Controlled Clinical Study Unknown status NCT01690845 Phase 2
15 Therapeutic Efficacy of L-Ornithine L-Aspartate Infusion in Patients With Acute Liver Failure: A Double- Blind, Randomized, Placebo- Controlled Study Unknown status NCT00470314 Phase 2 L-Ornithine L-Aspartate
16 A Phase II, Double-blinded, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Vitalliver in Patients With Decompensated Cirrhosis Completed NCT00562783 Phase 2 Vitaliver;Placebo
17 Emergency Use of OCR-002 (Ornithine Phenylacetate) in the Treatment of Patients With Acute Liver Failure Completed NCT01634230 Phase 2 OCR-002
18 Prospective Pilot Study Assessing Safety and Efficacy of Single Pass Albumin Dialysis in Patients With Acute on Chronic Liver Failure Completed NCT00764049 Phase 1, Phase 2
19 A Phase 2a Study to Evaluate the Safety and Tolerability of OCR-002 (Ornithine Phenylacetate) in the Treatment of Patients With Acute Liver Failure/Severe Acute Liver Injury Completed NCT01548690 Phase 2 Ornithine Phenylacetate
20 Phase 2 Evaluation of the Vitagen Extracorporeal Liver Assist Device (ELAD) System in the Management of the Patients With Fulminant Hepatic Failure Completed NCT00030225 Phase 2
21 Infusione Sistemica e Loco-regionale di N-Acetilcisteina Nel Prelievo di Fegato: Uno Studio Prospettico Randomizzato Controllato. Fase II. Completed NCT01394497 Phase 2 N-acetylcystein
22 Multicenter Phase II Safety and Preliminary Efficacy Study of 2 Dose Regimens of HepaStem in Patients With Acute on Chronic Liver Failure Recruiting NCT02946554 Phase 2
23 A Phase 2b Study to Evaluate Safety and Efficacy of LifeLiver (Bio Artificial Liver) in Acute or Acute-on-Chronic Liver Failure Patients Waiting Emergent Liver Transplantation Recruiting NCT03882346 Phase 2
24 An Interventional, Single Arm, Multicenter, Phase I/IIa Clinical Trial to Investigate the Efficacy and Safety of Allo-APZ2-ACLF for the Treatment of Acute-on-Chronic Liver Failure (ACLF) Recruiting NCT03860155 Phase 1, Phase 2
25 Mesenchymal Stem Cell Transplantation for Acute-on-Chronic Liver Failure Not yet recruiting NCT03863002 Phase 1, Phase 2
26 A Placebo-Controlled, Multicenter, Double-Blind, Randomized, Pharmacokinetic and Pharmacodynamic Trial of IDN-6556 in Subjects With Acute-on-Chronic Liver Failure Terminated NCT01937130 Phase 2 IDN-6556
27 An Open-Label, Multicenter, Historically-Controlled Study to Assess Safety and Efficacy of ELAD in Subjects With Acute Liver Failure (ALF) Terminated NCT01875874 Phase 2
28 Safety and Efficacy of the Extracorporeal Liver Assist Device (ELAD®) In Patients With Fulminant Hepatic Failure (FHF) Withdrawn NCT00832728 Phase 2
29 The Safety Study of Stemchymal® (Allogeneic Adipose-Derived Mesenchymal Stem Cells) Treating on Acute Liver Failure - An Open-Label, Single-Center Phase I Trial Not yet recruiting NCT03629015 Phase 1
30 Hepatocyte Transplantation for Acute Decompensated Liver Failure Withdrawn NCT01345565 Phase 1 human hepatocytes
31 G-CSF in Acute Liver Failure and Alcoholic Hepatitis - A Pilot Study Unknown status NCT01341951 Granulocyte colony stimulating factor
32 Relationship of Serological Growth Factors and Hepatic Progenitor Cells in Acute Liver Failure Unknown status NCT01312220
33 A Prospective Study of Evaluation of Minor Bleeding and Utility of Bleeding Criteria in Acute-on-chronic Liver Failure Patients in China Unknown status NCT03281252
34 Right and Extended Right Hepatectomy in Patients Beyond 70 Years of Age - Liver Function and Outcome Unknown status NCT01471262
35 Clinical and Basic Study for Pediatric Liver Transplantation Unknown status NCT02503384
36 Breath Test for Patients With Acute Liver Disease for Early Detection of the Need for Transplant or Recovery Unknown status NCT01435421
37 A Prospective Evaluation of the Role of Transient Elastography (Fibroscan) in Differentiating Patients of Acute Severe Viral Hepatitis and Acute on Chronic Liver Failure Unknown status NCT01866072
38 A Prospective Multicenter Study of Acute on Chronic Liver Failure in China Unknown status NCT02457637
39 A Retrospective Multicenter Study of HBV-related Pre-acute-on-chronic Liver Failure in China Completed NCT03281265
40 European Multicenter Plasma Exchange Trial (Empet): A Controlled, Open, Randomised, Multicenter Study In Patients With Acute Liver Failure Completed NCT00950508
41 Effect of Extracorporeal Liver Support by MARS and Prometheus on Albumin-Bound Substances in Acute-on-Chronic Liver Failure Completed NCT00407004
42 Evaluation of the Indocyangreen Elimination as a Prognostic Marker in Decompensated Cirrhosis and Acute Liver Failure Completed NCT00245310
43 Comparison of Risk of Hospitalization With Acute Liver Failure Between Patients With Type 2 Diabetes Initiating Saxagliptin and Those Initiating Other Oral Antidiabetic Treatments Completed NCT01086293
44 High Volume Plasma Exchange in Children With Acute Liver Failure and Acute on Chronic Liver Failure-A Prospective Pilot Study. Completed NCT02719210 Hypertonic 3% saline;Mannitol
45 High-Volume Plasma Exchange Versus Standard Medical Treatment in Patients With Acute Liver Failure-A Prospective Randomized Pilot Trial Completed NCT02718079 Prophylactic Antibiotics;N-acetyl-L-cysteine
46 Comparison of Two Extracorporeal Liver Support System (With or Without Recirculation) : MARS (Molecular Adsorbents Recirculating System) Versus SPAD (Single Pass Albumin Dialysis) in Severe Liver Failure. Completed NCT02310542
47 Unknown Cause of Acute Liver Failure: Determination of Early Mortality Predictive Factors Completed NCT02041637
48 A Pharmacoepidemiological Study to Examine Patient Characteristics, Drug Utilization Pattern and Crude Incidence Rates of Selected Outcomes in New Users of Ticagrelor, Clopidogrel and Prasugrel in National Swedish Registries Completed NCT01276275 Risk of selected safety events
49 The Effect of Prometheus (R) Liver Support Dialysis on Intracranial Pressure, Cerebral Oxidative Metabolism and Hemodynamics in Patients With Acute Liver Failure Completed NCT00655304
50 Frontal Electroencephalogram Variables Are Associated With Outcome and Stage of Hepatic Encephalopathy in Acute Liver Failure Completed NCT01878305

Search NIH Clinical Center for Hepatitis, Fulminant Viral

Cochrane evidence based reviews: liver failure, acute

Genetic Tests for Hepatitis, Fulminant Viral

Anatomical Context for Hepatitis, Fulminant Viral

MalaCards organs/tissues related to Hepatitis, Fulminant Viral:

40
Liver, Testes, Kidney, Heart, Brain, Thyroid, Bone Marrow

Publications for Hepatitis, Fulminant Viral

Articles related to Hepatitis, Fulminant Viral:

(show top 50) (show all 63)
# Title Authors PMID Year
1
Inherited IL-18BP deficiency in human fulminant viral hepatitis. 56 6
31213488 2019
2
Nosocomial Infections Are Frequent and Negatively Impact Outcomes in Hospitalized Patients With Cirrhosis. 61
31180922 2019
3
Predictors of Severity in Scrub Typhus. 61
31299836 2019
4
Exchange Transfusion and Cytarabine for Transient Abnormal Myelopoiesis in Hydrops Fetalis. 61
31015754 2019
5
Acute kidney injury in children with chronic liver disease. 61
29497824 2019
6
Dynamic Prognostication in Critically Ill Cirrhotic Patients With Multiorgan Failure in ICUs in Europe and North America: A Multicenter Analysis. 61
30106759 2018
7
Dengue shock syndrome complicated with acute liver failure and kidney injury, infective endocarditis, and deep vein thrombosis: a case report. 61
30373645 2018
8
Pyruvate dehydrogenase complex and lactate dehydrogenase are targets for therapy of acute liver failure. 61
29580866 2018
9
Evaluation of postoperative ascites after somatostatin infusion following hepatectomy for hepatocellular carcinoma by laparotomy: a multicenter randomized double-blind controlled trial (SOMAPROTECT). 61
30139340 2018
10
Hybrid Extracorporeal Therapies as a Bridge to Pediatric Liver Transplantation. 61
29652753 2018
11
A Case of Live Donor Liver Transplantation in Acute-on-Chronic Liver Failure with Budd-Chiari Syndrome: Donor and Recipient with Antiphospholipid Antibody Syndrome. 61
29959308 2018
12
Epidemiology of invasive pulmonary aspergillosis in patients with liver failure: Clinical presentation, risk factors, and outcomes. 61
29239266 2018
13
Outcome of 200 Pediatric Living Donor Liver Transplantations in India. 61
28849768 2017
14
Natural History and Treatment Outcomes of Severe Autoimmune Hepatitis. 61
28272079 2017
15
[Acute Liver Failure, Acute-On-Chronic Liver Failure, Hepatorenal Syndrome, Hepatopulmonary Syndrome and Portopulmonary Hypertension, Artificial Liver Support on the ICU]. 61
28641354 2017
16
[Thyroid storm associated with multiorganic dysfunction]. 61
28825582 2017
17
Extracorporeal support for patients with acute and acute on chronic liver failure. 61
26894968 2016
18
Abacavir-induced fulminant hepatic failure in a HIV/HCV co-infected patient. 61
26670894 2015
19
Management of alcohol recurrence before and after liver transplantation. 61
26193869 2015
20
Three decades of hepatitis B control with vaccination. 61
26328023 2015
21
Simple organ failure count versus CANONIC grading system for predicting mortality in acute-on-chronic liver failure. 61
25251968 2015
22
Magnetic resonance of the brain in chronic and acute liver failure. 61
24254992 2014
23
Pharmacologic cholinesterase inhibition improves survival in acetaminophen-induced acute liver failure in the mouse. 61
25139304 2014
24
Lung injury and its prognostic significance in acute liver failure. 61
24152589 2014
25
Hypoxic hepatitis and acute liver failure in a patient with newly onset atrial fibrillation and diltiazem infusion. 61
24042208 2013
26
Chronic hepatitis B in children and adolescents: epidemiology and management. 61
23529864 2013
27
Accumulation of xenotransplanted canine bone marrow cells in NOD/SCID/γc(null) mice with acute hepatitis induced by CCl4. 61
23411484 2013
28
[Nutrition in intensive care medicine: Part 2: special nutritional problems]. 61
23483230 2013
29
Reversal of dabigatran-induced bleeding with a prothrombin complex concentrate and fresh frozen plasma. 61
22997117 2012
30
Artificial liver support devices as treatment option for liver failure. 61
22482522 2012
31
Cell therapies for liver diseases. 61
22140063 2012
32
Incident user cohort study of risk for gastrointestinal bleed and stroke in individuals with major depressive disorder treated with antidepressants. 61
22466034 2012
33
Use of the molecular adsorbent recirculating system (MARS™) for the management of acute poisoning with or without liver failure. 61
22077243 2011
34
Multiple organ failure after an overdose of less than 0.4 mg/kg of colchicine: role of coingestants and drugs during intensive care management. 61
20969505 2010
35
Lack of therapeutic effects of gabexate mesilate on the hepatic encephalopathy in rats with acute and chronic hepatic failure. 61
20594263 2010
36
[Gelsolin - variety of structure and functions]. 61
20558869 2010
37
Thyroid storm with multiorgan failure. 61
20146655 2010
38
Serum peptide profiles during progression of chronic hepatitis B virus infection to liver failure. 61
20586930 2010
39
Moderate hypothermia with intracranial pressure monitoring as a therapeutic paradigm for the management of acute liver failure: a systematic review. 61
19847396 2010
40
Relative adrenal insufficiency in a patient with liver disease. 61
20611008 2009
41
Relative adrenal insufficiency in a patient with liver disease. 61
19382344 2009
42
Management of chronic hepatitis B in children. 61
19322053 2009
43
Clinical relevance of non-cardiac determinants of natriuretic peptide levels. 61
19012517 2008
44
NMDA receptors in hyperammonemia and hepatic encephalopathy. 61
17701332 2007
45
Artificial liver support system in China: a review over the last 30 years. 61
16684218 2006
46
Parenteral nutrition in adult inpatients with functioning gastrointestinal tracts: assessment of outcomes. 61
16581410 2006
47
Mild hypothermia prevents brain edema and attenuates up-regulation of the astrocytic benzodiazepine receptor in experimental acute liver failure. 61
15826719 2005
48
Oral acute toxicity of HEPALIP FORTE in rats. 61
16232135 2003
49
Aetiology and prognostic factors in acute liver failure in India. 61
12753342 2003
50
Endothelin is an important determinant of renal function in a rat model of acute liver and renal failure. 61
11772977 2002

Variations for Hepatitis, Fulminant Viral

ClinVar genetic disease variations for Hepatitis, Fulminant Viral:

6 ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 IL18BP NM_001039660.2(IL18BP):c.508-19_528deldeletion risk factor 689420 11:71712806-71712845 11:72001760-72001799

Expression for Hepatitis, Fulminant Viral

Search GEO for disease gene expression data for Hepatitis, Fulminant Viral.

Pathways for Hepatitis, Fulminant Viral

GO Terms for Hepatitis, Fulminant Viral

Sources for Hepatitis, Fulminant Viral

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....